More importantly, we demonstrated that targeting the kinase activity of TAK1 with the selective inhibitor LYTAK1 enhanced the anti-tumor activity of chemotherapeutic drugs in vivo in an orthotopic model of pancreatic cancer, indicating that the inhibition of the kinase activity of TAK1 could be a valid approach to reverting the intrinsic chemoresistance of pancreatic cancer (Melisi et al., 2011). Here, MAP3K7 is linked to pancreatic neoplasm.